RB Capital Management LLC Has $245,000 Stock Position in Pfizer Inc. (NYSE:PFE)

RB Capital Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 24.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,522 shares of the biopharmaceutical company’s stock after selling 2,823 shares during the period. RB Capital Management LLC’s holdings in Pfizer were worth $245,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer during the fourth quarter worth approximately $37,000. Creative Capital Management Investments LLC increased its stake in Pfizer by 30.1% in the fourth quarter. Creative Capital Management Investments LLC now owns 2,988 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 692 shares during the last quarter. Mine & Arao Wealth Creation & Management LLC. increased its stake in Pfizer by 21.7% in the fourth quarter. Mine & Arao Wealth Creation & Management LLC. now owns 8,445 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 1,507 shares during the last quarter. Triumph Capital Management grew its stake in shares of Pfizer by 64.6% during the fourth quarter. Triumph Capital Management now owns 24,820 shares of the biopharmaceutical company’s stock worth $715,000 after buying an additional 9,744 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Pfizer by 12.2% during the fourth quarter. Victory Capital Management Inc. now owns 5,071,853 shares of the biopharmaceutical company’s stock worth $146,019,000 after buying an additional 552,778 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Price Performance

PFE stock opened at $27.08 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The firm’s fifty day moving average is $26.87 and its 200 day moving average is $28.25. The firm has a market cap of $153.34 billion, a P/E ratio of 75.47, a P/E/G ratio of 1.15 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 EPS. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.20%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.